Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Magnesium oxide versus macrogol/electrolytes for prevention of opioid-induced constipation in palliative cancer care
NL-OMON33671Phase 3Active, not recruiting
- Sponsor
- University Medical Center Utrecht
- Start
- Jan 2010
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of magnesium oxide and polyethylene glycol 3350 + electrolytes in constipation (2 arms), sponsored by University Medical Center Utrecht. Primary endpoint: Degree of constipation at 2 weeks. Started Jan 2010; status: active, not recruiting.
02
Drugs
magnesium oxidepolyethylene glycol 3350 + electrolytes
03
Conditions
constipation
Beyond the preview
Go deeper on NL-OMON33671.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON33671.